April 16, 2015

Arch Therapeutics' AC5(TM) Compared Favorably vs. Commercially Available Combination Hemostat in Animal Study

Data Shows Time to Hemostasis With AC5 Significantly Less Than Compared Product

FRAMINGHAM, MA -- (Marketwired) -- 04/16/15 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced that an independent third party has obtained favorable data from an animal study that compared the hemostatic activity of AC5 with a commercially available branded hemostat consisting of a flowable gelatin combined with thrombin.

In this study, full thickness penetrating wounds were surgically created in rat livers, which are highly vascularized parenchymal organs, and then either AC5™ or gelatin-thrombin hemostat was applied in order to stop the bleeding. The time to hemostasis (TTH), which is the time required to stop bleeding, was measured.

The average TTH after application of AC5 was significantly less than 30 seconds, whereas the average TTH after application of the gelatin-thrombin hemostat was over 200% longer.

AC5 was maintained at room temperature without requiring cold storage, whereas the thrombin component of the gelatin-thrombin hemostat was maintained frozen during storage, in accordance with its prescribing directions. This is a common constraint of many commercial hemostatic agents that are derived from blood-products. Such products also require a multi-step preparation procedure prior to use.

The thrombin component of the gelatin-thrombin hemostat is made from pooled human plasma and, therefore, carries a risk of transmitting infectious agents. In general, products of human origin present increased risk due to the potential to transfer infections. The gelatin component of the gelatin-thrombin hemostat is derived from pigskins. Gelatin can carry an increased specific risk for causing allergic reactions in some patients because it is animal sourced. AC5 contains a self-assembling peptide comprising naturally occurring amino acids that are not sourced from humans or animals.

The study group intends to submit the data for publication, at which time additional details would be made publicly available. This study is one of series of animal trials comparing AC5 with currently marketed hemostatic products that are used in surgical procedures.

Terrence W. Norchi, MD, President and CEO of Arch Therapeutics, said, "We believe that

the Arch technology holds great potential in addressing a range of unmet clinical needs, the first of which is surgical hemostasis. Data from the studies conducted to date indicate that AC5 continues to perform favorably versus well-established hemostatic products, including those based on cellulose, gelatin, gelatin-thrombin, and fibrin. Other noteworthy features of AC5 include ease of use, simple preparation, room temperature storage and lack of human or other animal sourcing."

The research was led by Rudolf Urbanics, MD, PhD, and Domokos Csukas, DVM at Semmelweis University Faculty of Medicine in Budapest, Hungary within the Department of Surgical Research and Techniques. The research was sponsored by Arch. Also part of the research team was Dr. Rutledge Ellis-Behnke, Director of the Nanomedicine Translational Think Tank in the Department of Ophthalmology at the Medical Faculty Mannheim of the University of Heidelberg in Germany. Dr. Ellis-Behnke is also affiliated with three U.S. academic institutions, and he is an advisor to and co-founder of Arch.

About Arch Therapeutics, Inc.

Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as the AC5 Surgical Hemostatic Device ™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

On Behalf of the Board,

Terrence W. Norchi, MD
Arch Therapeutics, Inc.

Contact:

ARTH Investor Relations
Toll Free: *+1-855-340-ARTH* (2784) (US and Canada)
Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com

Or

Richard Davis
Chief Financial Officer
Arch Therapeutics, Inc.
Phone: *617-431-2308*
Email: rdavis@archtherapeutics.com
Website: www.archtherapeutics.com

Source: Arch Therapeutics, Inc.